时间限制的饮食和刺激性肠综合征的症状严重程度:试点研究结果
Maria Thompson Clausen1,2, Henrik Sverdrup1,2, Asgeir Brevik3
1Department of Health and Exercise, School of Health Sciences, Kristiania University College of Applied Sciences, P.O. Box 1190, N-0107 Oslo, Norway.
Nutrients
|March 14, 2026
概括
时间限制饮食 (TRE) 在一项试点研究中显著降低了刺激性肠综合征 (IBS) 症状. 这种饮食方法对管理IBS有希望,改善身体和心理健康.
科学领域:
- 胃肠病学 胃肠病学
- 饮食干预 饮食干预
- 功能性胃肠道疾病 功能性胃肠道疾病
背景情况:
- 刺激性肠综合征 (IBS) 影响了大约5-10%的人口.
- 许多IBS患者在目前的治疗方法下经历了不充分的症状缓解.
- 对IBS需要新的治疗策略.
研究的目的:
- 调查时间限制饮食 (TRE) 在缓解IBS症状方面的有效性.
- 评估16:8 TRE协议对IBS患者结局的影响.
主要方法:
- 一个单一组,前后试点研究设计.
- 包括被诊断患有IBS的参与者.
- 一个为期8周的16:8 TRE干预 (16小时的禁食,8小时的进食窗口).
- 在基线和干预后使用IBS症状严重程度表 (IBS-SSS) 评估症状严重程度.
主要成果:
- 在134名注册参与者中,共有97人完成了这项研究.
- 在IBS-SSS得分中的显著平均降低 (-100.2,p < 0.001).
- 在IBS亚型中观察到的症状改善:IBS便秘 (-125.2),IBS腹 (-76.0) 和IBS混合 (-93.1).
- 参与者报告说,他们的身体和精神健康有所改善.
结论:
- 时间限制饮食 (TRE) 证明了作为IBS症状管理的行为干预的潜力.
- TRE可能是一个有希望的,可访问的策略,以改善IBS患者的生活质量.
- 需要进一步的受控试验来证实这些初步发现.
相关概念视频
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
998
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
998
Irritable Bowel Syndrome I: Introduction
1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
Irritable Bowel Syndrome III: Medical and Nursing Management
961
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
961
Drugs for Treatment of Diarrhea-Predominant IBS
833
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
833
Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K


